NHS Greater Glasgow & Clyde Area Drug and Therapeutics Committee
Greater Glasgow and Clyde Medicines
Medicines Update

Fluticasone furoate and vilanterol (Relvar Ellipta®)

Fluticasone furoate and vilanterol (Relvar Ellipta®)

This product has been launched for both COPD and asthma, although SMC advice has been issued for COPD only at this stage. A more detailed article will appear in a future edition but prescribers should be aware of the following points:

  • This contains high potency inhaled corticosteroid (92 micrograms of fluticasone furoate once daily is approximately equivalent to fluticasone propionate 250 micrograms twice daily according to SPC for the asthma indication).
  • The name and / or colour of this device may inadvertently lead patients to confuse it as a 'reliever'. Careful counselling to avoid overuse is advised.
  • The device has a six week expiry once removed from the foil pouch packaging.
  • Only 92 / 22 microgram strength licensed for COPD.
  • See NHSGGC Formulary, COPD guideline and COPD Inhaler Device Guide for preferred options.

 

Next article: Guidelines update 

 

Previous article: Kid's corner: specials